Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval

Feb 24 2014

• By Sue Sutter

Related Content

Paladin’s <em>Impavido</em> Could Set A Price Tag For Priority Review Vouchers

Jun 20 2013

FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim

Nov 20 2013

CHMP Clears Pierre Fabre’s Hemangiol For Children, Under Rarely Used Pediatric Pathway

Feb 21 2014

Another Chance to Make Priority Review Vouchers Work

Aug 22 2012

BioMarin’s Vimizim Secures Broad Label In Morquio A Syndrome

Feb 18 2014

Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors

Sep 21 2011

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

Aug 29 2011

Related Companies

BioMarin Pharmaceutical Inc.

Novartis AG

Johnson & Johnson

Paladin Pharma Inc.

Sanofi Genzyme

Additional Topics

United States Approvals BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window